Human Immunoglobulin G

Dosing for Human Immunoglobulin G is highly individualized and is almost always based on the patient's body weight (mg/kg or g/kg).

• Primary Immunodeficiency (PI): The standard starting dose is typically 300 mg/kg to 600 mg/kg administered every 3 to 4 weeks for IVIG. For subcutaneous (SCIG) use, the total monthly dose is often divided into weekly or bi-weekly infusions.
• Immune Thrombocytopenic Purpura (ITP): A common regimen is 1 g/kg daily for two consecutive days, or 400 mg/kg daily for five consecutive days, depending on the urgency of the platelet count increase.
• CIDP: The loading dose is usually 2 g/kg divided over 2 to 5 days, followed by maintenance doses of 1 g/kg every 3 weeks.

Human Immunoglobulin G is widely used in children, particularly for Kawasaki Disease and Primary Immunodeficiency.

• Kawasaki Disease: A single high dose of 2 g/kg is typically administered over 10 to 12 hours, ideally within the first 10 days of fever onset.
• Pediatric PI: Dosing is similar to adults, starting at 300-600 mg/kg every 3-4 weeks.
• Safety Note: Pediatric patients must be monitored closely for volume overload, especially in infants and small children.

Renal Impairment

Patients with pre-existing kidney disease or those at risk for renal failure (such as those with diabetes or who are over age 65) require extreme caution. Healthcare providers will typically use the minimum concentration available and the slowest infusion rate possible. Dosage may be reduced if creatinine levels rise significantly.

Hepatic Impairment

No specific dosage adjustments are generally required for liver impairment, as IgG is not metabolized by the liver. However, patients with liver disease may be at higher risk for thrombosis (blood clots), requiring careful monitoring.

Elderly Patients

Patients over 65 years of age are at increased risk for adverse reactions, particularly renal dysfunction and thromboembolic events. Lower infusion rates and thorough hydration are mandatory for this population.

Human Immunoglobulin G is administered by a healthcare professional in a clinic, hospital, or through a home-infusion service.

• Hydration: It is critical to be well-hydrated before the infusion begins. Drink plenty of water in the 24 hours leading up to your appointment.
• Pre-medication: Your doctor may prescribe acetaminophen (Tylenol) and an antihistamine (like Benadryl) 30 to 60 minutes before the infusion to prevent common side effects like headache and fever.
• Infusion Rate: The infusion must start very slowly (e.g., 0.01 mL/kg/minute). If tolerated, the nurse will gradually increase the rate every 15-30 minutes.
• Storage: Most liquid formulations must be stored in the refrigerator (2°C to 8°C) and protected from light, though some brands allow for room-temperature storage for limited periods. Never shake the vial, as this can damage the proteins.

If you miss an infusion appointment, contact your healthcare provider immediately to reschedule. Maintaining consistent trough levels (the lowest amount of drug in your blood before the next dose) is vital for preventing infections or disease flares. Do not double the dose at the next appointment to 'catch up.'

An overdose of Human Immunoglobulin G is rare because it is administered by professionals, but it can lead to 'hyperviscosity syndrome' (thickening of the blood).

• Symptoms: Severe headache, confusion, shortness of breath, or swelling in the legs.
• Emergency Measures: Treatment involves stopping the infusion immediately and providing supportive care, which may include intravenous fluids to thin the blood.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency without medical guidance. Regular blood tests are required to ensure the dose is effective and safe.

Side effects are most common during the first few infusions or when switching brands. These are often related to the rate of infusion.

• Headache: This is the most frequently reported side effect. It can range from a mild tension-type headache to a severe migraine-like sensation. It usually begins toward the end of the infusion or a few hours later.
• Fever and Chills: Often referred to as 'flu-like symptoms,' these typically resolve within 24 to 48 hours.
• Fatigue: Many patients feel significantly tired or 'wiped out' for a day or two following treatment.
• Injection Site Reactions: For subcutaneous (SCIG) users, redness, swelling, and itching at the needle site are very common but usually mild.

• Nausea and Vomiting: Mild gastrointestinal upset may occur during the infusion.
• Back Pain or Joint Pain: A dull ache in the lower back or large joints.
• Blood Pressure Changes: Both increases (hypertension) and decreases (hypotension) in blood pressure can occur during administration.
• Tachycardia: A racing heart or palpitations.

• Aseptic Meningitis: A non-infectious inflammation of the lining of the brain. Symptoms include severe headache, neck stiffness, light sensitivity, and fever. It usually appears within 48 hours of an infusion and resolves without permanent damage.
• Hemolytic Anemia: IgG can sometimes contain antibodies that cause the destruction of the patient's own red blood cells. Symptoms include pale skin, dark urine, and extreme weakness.
• Transfusion-Related Acute Lung Injury (TRALI): A rare but serious lung reaction characterized by severe respiratory distress and low oxygen levels.

> Warning: Stop taking Human Immunoglobulin G and call your doctor immediately if you experience any of these symptoms.

• Anaphylaxis: Signs include hives, swelling of the throat or tongue, difficulty breathing, and fainting. This is most common in patients with IgA deficiency.
• Thrombosis (Blood Clots): Look for pain, warmth, or swelling in one leg (DVT), sudden shortness of breath (PE), or signs of a stroke (slurred speech, one-sided weakness).
• Acute Renal Failure: Signs include a sudden decrease in urination, swelling in the ankles or feet, and rapid weight gain.
• Severe Skin Reactions: Stevens-Johnson Syndrome is extremely rare but possible; watch for a blistering rash or peeling skin.

Prolonged use of Human Immunoglobulin G is generally considered safe, but patients should be monitored for:

• Iron Overload: Rare, but can occur in patients receiving very high doses over many years.
• Volume Overload: Chronic infusions can strain the heart in patients with pre-existing congestive heart failure.
• Pathogen Transmission: While the risk is mathematically near zero due to modern screening, IgG is a human blood product, and the theoretical risk of transmitting infectious agents (including prions) exists.

The FDA has issued several Black Box Warnings for Human Immunoglobulin G products:

1. 1Renal Dysfunction and Acute Renal Failure: Cases of kidney failure and death have occurred, particularly with products containing sucrose as a stabilizer. Patients with pre-existing renal insufficiency, diabetes, or sepsis are at highest risk.
2. 2Thrombosis: Blood clots may occur even in patients without risk factors. Risk is higher with high doses and rapid infusion rates.

Report any unusual symptoms to your healthcare provider. Most side effects can be managed by adjusting the infusion rate or changing the pre-medication regimen.

Human Immunoglobulin G is a complex biologic product. Patients must be screened for specific risk factors before the first dose. Because it is derived from human plasma, it carries a theoretical risk of transmitting infectious agents, although modern manufacturing processes make this risk extremely low.

No FDA black box warnings are omitted here; they are central to the safety profile of Human Immunoglobulin G.

• Renal Warning: Human Immunoglobulin G has been associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Use with extreme caution in patients with any degree of renal insufficiency. Ensure patients are not volume-depleted before infusion.
• Thrombotic Events Warning: Thrombosis (blood clotting) may occur with immune globulin products. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, and hyperviscosity.

• Allergic Reactions / Anaphylaxis: Patients with selective IgA deficiency who have developed antibodies against IgA are at high risk for severe life-threatening allergic reactions. Testing for IgA levels is often performed before starting therapy.
• Aseptic Meningitis Syndrome (AMS): This syndrome may occur more frequently with high doses (2 g/kg) or rapid infusion. It is characterized by severe headache, nausea, vomiting, and nuchal rigidity (stiff neck).
• Hemolysis: IgG products can contain blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin test (Coombs' test) and hemolysis.
• Hyperproteinemia: High levels of protein in the blood can lead to 'pseudohyponatremia' (a false low sodium reading on blood tests). This requires careful interpretation by a physician.

To ensure safety, your healthcare provider will require regular laboratory monitoring:

• Renal Function: Baseline BUN and Serum Creatinine must be checked before starting and periodically thereafter.
• Urine Output: Monitoring for any decrease in urination during and after the infusion.
• Blood Counts: Complete Blood Count (CBC) to check for signs of hemolysis or infection.
• Vital Signs: Blood pressure, heart rate, and temperature are monitored every 15-30 minutes during the infusion.
• IgG Trough Levels: For PI patients, blood is drawn just before an infusion to ensure the dose is high enough to maintain protection.

Some patients experience dizziness or fatigue after an infusion. It is recommended that you do not drive or operate heavy machinery for at least 24 hours after your first few infusions until you know how the medication affects you.

There is no direct chemical interaction between alcohol and Human Immunoglobulin G. However, alcohol can cause dehydration, which significantly increases the risk of headaches and kidney strain during an infusion. It is best to avoid alcohol for 24 hours before and after treatment.

Stopping Human Immunoglobulin G suddenly in patients with PI can lead to a rapid return of severe infections. In patients with CIDP or ITP, discontinuation may cause a relapse of symptoms. Always consult your specialist before stopping treatment. There is no 'withdrawal syndrome' in the traditional sense, but the underlying disease will no longer be suppressed.

> Important: Discuss all your medical conditions, especially kidney disease, heart disease, or a history of blood clots, with your healthcare provider before starting Human Immunoglobulin G.

There are no absolute drug-drug contraindications where the combination is guaranteed to be fatal; however, the following should be avoided:

• Live Virus Vaccines (e.g., MMR, Varicella, Rotavirus): Human Immunoglobulin G contains antibodies that will neutralize the vaccine virus before your body can develop its own immunity. This renders the vaccine ineffective. Live vaccines should generally be delayed for at least 3 to 11 months after an IgG infusion.

• Loop Diuretics (e.g., Furosemide/Lasix): These drugs can cause dehydration, which significantly increases the risk of IgG-induced acute renal failure.
• Nephrotoxic Agents (e.g., NSAIDs like Ibuprofen, Gentamicin, IV Contrast): Taking other drugs that stress the kidneys while receiving IgG can lead to sudden kidney collapse.
• Estrogen-Containing Contraceptives: Estrogen increases the risk of blood clots. When combined with the thrombotic risk of IgG, the danger of stroke or pulmonary embolism is heightened.

• Blood Thinners (Warfarin, Heparin): While not a direct interaction, the use of IgG in patients with bleeding disorders requires careful coordination with anticoagulation therapy.
• Corticosteroids: Often used together, but long-term use of both can increase the risk of fluid retention and electrolyte imbalances.

• Hydration Status: The most important 'interaction' is with water. Dehydration increases the viscosity of the blood, making the side effects of IgG much more severe.
• Salt Intake: High salt intake can contribute to fluid retention, which may complicate the infusion in patients with heart or kidney issues.

• St. John’s Wort: While no direct interaction exists, St. John’s Wort can affect the metabolism of other medications you may be taking alongside IgG.
• Licorice Root: Can cause sodium retention and potassium loss, potentially complicating the fluid balance required for safe IgG administration.

Human Immunoglobulin G can significantly interfere with several laboratory tests:

• Serological Tests: After an infusion, your blood will test positive for many antibodies (like Hepatitis or Measles) that you didn't produce yourself. This can lead to false-positive results.
• Blood Glucose: Some IgG products contain maltose, which can cause falsely high blood sugar readings on certain glucose meters. This can lead to dangerous over-administration of insulin.
• Coombs' Test: IgG can cause a false-positive direct antiglobulin test, complicating blood typing and cross-matching.
• Erythrocyte Sedimentation Rate (ESR): IgG may cause a transient rise in ESR that does not reflect a new infection.

For each major interaction, the management strategy involves either timing the medications differently (as with vaccines), ensuring aggressive hydration (as with diuretics), or using alternative testing methods (as with glucose monitoring).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers.

There are specific scenarios where Human Immunoglobulin G must NEVER be used because the risks far outweigh any potential benefits:

• History of Anaphylaxis to Immune Globulin: If a patient has had a life-threatening allergic reaction to any human immunoglobulin product in the past, they should not receive it again unless in a highly controlled desensitization setting.
• Selective IgA Deficiency with Antibodies to IgA: Patients who lack IgA and have developed 'anti-IgA' antibodies can experience immediate, severe anaphylaxis upon receiving IgG, as most IgG products contain trace amounts of IgA.
• Hyperprolinemia Type I: Certain brands of IgG (such as Privigen) use the amino acid L-proline as a stabilizer. Patients with this rare genetic metabolic disorder cannot process proline, making these specific brands contraindicated.

These are conditions where the doctor must perform a careful risk-benefit analysis:

• Pre-existing Acute Renal Failure: If the kidneys are already failing, IgG may worsen the condition to the point of requiring dialysis.
• Congestive Heart Failure (CHF): Because IgG is a protein-rich solution that draws fluid into the bloodstream, it can cause 'volume overload,' leading to acute heart failure or pulmonary edema (fluid in the lungs).
• Hyperviscosity Syndromes: Patients with very high protein levels (like those with certain types of multiple myeloma) may have 'thick' blood that becomes dangerously viscous after an IgG infusion.

Patients who are allergic to other blood-derived products (such as albumin or clotting factors) may have an increased risk of reacting to Human Immunoglobulin G. Additionally, some formulations contain trace amounts of detergents or chemicals used in the manufacturing process (like polysorbate 80); sensitivity to these components should be evaluated.

> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic disorders or previous reactions to blood transfusions, before prescribing Human Immunoglobulin G.

Human Immunoglobulin G is classified as FDA Pregnancy Category C (or B, depending on the specific brand). There are no well-controlled studies in pregnant women; however, clinical experience suggests that IgG does not cause birth defects.

• Trimester-Specific Risks: IgG is known to cross the placenta, especially during the third trimester. This is often used therapeutically to treat conditions in the fetus, such as fetal alloimmune thrombocytopenia.
• Clinical Use: It is frequently used during pregnancy to treat maternal ITP or to provide protection against infections in mothers with PI. The benefits usually outweigh the theoretical risks.

Immunoglobulins are a natural component of breast milk. While Human Immunoglobulin G passes into breast milk, it is unlikely to be absorbed by the infant's digestive tract in a way that would cause harm. Most experts consider IgG therapy compatible with breastfeeding, though the infant should be monitored for any unusual symptoms like diarrhea or skin rash.

Human Immunoglobulin G is approved for use in children as young as newborns for certain indications (like Kawasaki Disease).

• Growth Effects: There is no evidence that IgG therapy affects long-term growth or development.
• Dosing: Dosing is strictly weight-based. Children are more susceptible to fluid shifts, so infusion rates must be carefully calculated and monitored.
• Conditions NOT Approved: IgG is generally not used for 'frequent colds' or minor immune system delays in children unless a specific deficiency is diagnosed.

Patients over age 65 are at the highest risk for the most serious complications of IgG therapy.

• Renal Risk: Age-related decline in kidney function makes elderly patients more prone to acute renal failure.
• Thrombosis: The risk of stroke and heart attack is significantly higher in this population.
• Administration: Slower infusion rates and lower concentrations (5% instead of 10%) are often recommended for geriatric patients.

In patients with a Glomerular Filtration Rate (GFR) below 60 mL/min/1.73m², IgG should be used with extreme caution.

• Adjustments: The dose may not be changed, but the rate of administration is often halved.
• Dialysis: IgG is a large molecule and is not significantly cleared by standard hemodialysis. Dosing does not usually need to be timed around dialysis sessions.

No dose adjustments are required for patients with liver disease (Child-Pugh Class A, B, or C). However, these patients should be monitored for 'hypercoagulability' (increased clotting risk), as the liver produces many of the body's natural anticoagulants.

> Important: Special populations require individualized medical assessment and often more frequent laboratory monitoring to ensure safety.

At the molecular level, Human Immunoglobulin G acts through several pathways:

1. 1Antigen Binding: The Fab (Fragment, antigen-binding) portion of the IgG molecule binds to specific epitopes on pathogens, neutralizing them.
2. 2Fc Receptor Blockade: In autoimmune diseases, the Fc (Fragment, crystallizable) portion of the infused IgG binds to Fc receptors on macrophages, preventing them from 'eating' the patient's own platelets or myelin.
3. 3Complement Regulation: IgG can bind to and neutralize C3a and C5a (complement fragments), reducing the inflammatory cascade.
4. 4Cytokine Modulation: It shifts the balance of the immune system from a pro-inflammatory state to an anti-inflammatory state by increasing the production of interleukin-10 (IL-10).

• Onset of Effect: In ITP, platelet counts usually begin to rise within 24 to 72 hours. In PI, protection against infection is immediate upon reaching therapeutic levels.
• Duration: The effects of a single dose typically last 3 to 4 weeks, which is why maintenance dosing is usually scheduled monthly.
• Tolerance: There is no evidence of pharmacological tolerance; the drug remains effective over decades of use.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV), 60-70% (Subcutaneous) |

| Protein Binding | Minimal (it is a protein itself) |

| Half-life | 21 to 30 days |

| Tmax | Immediate (IV), 2-4 days (Subcutaneous) |

| Metabolism | Lysosomal Proteolysis |

| Excretion | Renal <1%, Fecal <1% (broken down into amino acids) |

• Molecular Formula: Complex glycoprotein (approx. C6332H9812N1688O1984S42 for IgG1)
• Molecular Weight: Approximately 150,000 Daltons (150 kDa)
• Solubility: Highly soluble in water-based solutions at slightly acidic pH (4.0 to 6.0)
• Structure: A 'Y' shaped molecule consisting of two heavy chains and two light chains held together by disulfide bonds.

Human Immunoglobulin G is the primary member of the Human Immunoglobulin G [EPC] class. Related medications include specialized hyper-immune globulins (like RhoGAM for Rh-negative pregnancy or Rabies Immune Globulin), which contain high titers of antibodies against a single specific antigen.